PRAX — Praxis Precision Medicines, Inc.

Summary of PRAX (Praxis Precision Medicines) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Operating Expenses: Totaled $97 million, up from $71.4 million in Q4 2024. This includes $77.5 million for R&D and $19.5 million for G&A.
• Full Year Operating Expenses: Reached $326 million in 2025, compared to $209 million in 2024, driven by increased spending on clinical programs.
• Cash Position: Ended Q4 with $926 million in cash and equivalents, significantly up from $469 million at the end of 2024. Pro forma cash position post-January public offering is approximately $1.5 billion, expected to fund operations into 2028.

2. Strategic Updates and Business Highlights

• Clinical Achievements: Positive readouts and FDA interactions for ulixacaltamide (essential tremor), relutrigine (SCN2A and 8A DEEs), and vormatrigine (focal epilepsy).
• NDA Submissions: Two NDAs submitted in Q1 2026 for ulixacaltamide and relutrigine, with expectations for approval in the near future.
• Upcoming Data: Anticipated top-line results for vormatrigine's POWER1 study and elsunersen's EMBRAVE data in Q2 2026, with enrollment for POWER2 expected to complete in the second half of 2026.
• Market Potential: Ulixacaltamide has an estimated annual revenue potential of over $10 billion, while relutrigine could reach $5 billion, and vormatrigine around $4 billion.

3. Forward Guidance and Outlook

• Commercial Launch Preparations: Building infrastructure for ulixacaltamide and relutrigine launches, including hiring and inventory management.
• R&D Day Planned: Upcoming events to discuss clinical and preclinical programs, as well as commercial strategies.
• Focus on Disease Awareness: Initiatives to educate prescribers and patients about essential tremor and developmental epileptic encephalopathies (DEE).

4. Bad News, Challenges, or Points of Concern

• No Priority Review for Ulixacaltamide: The decision was strategic, considering potential market dynamics and pricing strategies under the Inflation Reduction Act (IRA).
• FDA Review Timeline Uncertainty: No indication of advisory committee meetings for either NDA, which may affect timelines.
• Competitive Landscape: Increasing competition in the epilepsy market, particularly with emerging therapies targeting potassium channels, may impact market share for vormatrigine.

5. Notable Q&A Insights

• Titration Protocol for Ulixacaltamide: Discussions with the FDA about alternative titration schedules are ongoing, with a focus on patient tolerability.
• Market Understanding: Strong grasp of prescriber distribution, with a focus on general neurologists for ulixacaltamide, which is expected to be widely prescribed.
• Relutrigine's Broad Label Potential: EMERALD study aims to assess efficacy across diverse DEE populations, with no specific quotas for different etiologies.
• Retention Rates for Vormatrigine: Early indicators show high retention rates in open-label extensions, suggesting strong patient satisfaction and potential for long-term use.
• Synergies Between Launches: While there is overlap in prescriber bases, the company plans to execute separate go-to-market strategies for ulixacaltamide and relutrigine to maximize impact.

Overall, 2025 was a transformative year for Praxis, marked by significant clinical advancements and strategic preparations for upcoming product launches, despite facing challenges related to regulatory timelines and competitive pressures.